CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Elicit Therapeutics Inc. - ELTX CFD

8.0666
3.24%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0768
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 8.3366
Open 7.9766
1-Year Change 725.82%
Day's Range 7.9766 - 8.2766
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 14, 2024 8.0666 0.0900 1.13% 7.9766 8.2966 7.9766
Jun 13, 2024 8.3366 0.1600 1.96% 8.1766 8.3366 8.0166
Jun 12, 2024 8.3266 0.2500 3.10% 8.0766 8.4166 8.0766
Jun 11, 2024 7.9966 0.2200 2.83% 7.7766 8.0666 7.7766
Jun 10, 2024 7.9366 0.2900 3.79% 7.6466 7.9666 7.6466
Jun 7, 2024 7.7966 -0.1900 -2.38% 7.9866 8.0166 7.5466
Jun 6, 2024 7.8266 0.1700 2.22% 7.6566 8.0766 7.5266
Jun 5, 2024 7.8766 0.2900 3.82% 7.5866 7.8866 7.5366
Jun 4, 2024 7.4866 -0.2100 -2.73% 7.6966 7.6966 7.2866
Jun 3, 2024 7.6866 -0.0900 -1.16% 7.7766 7.7766 7.3766
May 31, 2024 7.7166 0.4300 5.90% 7.2866 7.7566 7.2866
May 30, 2024 7.3766 -0.2000 -2.64% 7.5766 7.5766 7.2266
May 29, 2024 7.4766 -0.2300 -2.98% 7.7066 7.7066 7.3766
May 28, 2024 7.9866 -0.4100 -4.88% 8.3966 8.4966 7.7766
May 24, 2024 8.3266 0.1300 1.59% 8.1966 8.4766 7.0566
May 23, 2024 8.8166 0.2900 3.40% 8.5266 8.8766 8.2766
May 22, 2024 8.8166 0.1600 1.85% 8.6566 8.9766 8.2066
May 21, 2024 8.8066 -1.0700 -10.83% 9.8766 9.8766 8.4766
May 20, 2024 9.8066 -0.2400 -2.39% 10.0466 10.1366 9.4766
May 17, 2024 10.0066 0.1800 1.83% 9.8266 10.2266 9.4666

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Angion Biomedica Corp. Company profile

About Angion Biomedica Corp

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US

News

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

ECB preview: A cut, but how many more?

After months of waiting, a rate cut from the ECB on Thursday looks like a done deal. Data from Reuters shows markets pricing in a 96% chance of a 25-basis point cut from the European Central Bank following Thursday’s policy meeting.

08:54, 4 June 2024

PCE Index Preview: Forecasts point to no change in headline or core inflation from a month earlier

The markets continue to look for signals of disinflation in the United States. The latest PCE Index data, the US Federal Reserve’s preferred inflation gauge, is released on May 31, 2024.

12:44, 29 May 2024

Gold and Silver recover from last week’s pullback but face resistance ahead of US PCE

Gold and Silver move higher after last week’s pullbacks but the precious metals are struggling with resistance ahead of the US PCE release.

15:46, 28 May 2024

People also watch

ETH/USD

3,562.17 Price
+4.340% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,677.60 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.49 Price
+3.860% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

66,166.65 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading